Alpha 2 adrenergic receptors play a major role in the sympathetic nervous system control over vascular function. Alpha 2 receptors in the vasomotor center modulate sympathetic outflow. Stimulation of presynaptic alpha 2 receptors inhibits neurotransmitter release. Postsynaptic alpha 2 receptors are found on vascular smooth muscle where they mediate contraction, on endothelial cells where they stimulate release of endothelial derived relaxing factor, and on platelets where they enhance aggregation. Three genes encoding distinct subtypes of alpha 2 adrenergic receptors have been identified in mouse and man. It has not been possible to identify the physiologic role of the different alpha 2 subtypes using pharmacologic approaches or by applying the techniques of molecular biology. However, recently developed techniques of experimental mammalian embryology make it possible to selectively alter alpha 2 adrenergic receptor genes in mice. Using these techniques we propose to create strains of mice which have a targeted gene disruption for each subtype of alpha 2 adrenergic receptor. By studying alpha 2 mediated changes in vascular function in these mice it should be possible to identify specific roles for each of the receptor subtypes. These studies may provide incentive for the development of more selective agonists and antagonist for specific alpha 2 adrenergic and physiologic receptor subtypes. Furthermore, the genetically altered mice may prove useful in studying the pharmacologic and physiologic properties of newly developed drugs. Finally, the phenotypes of these recombinant mice may provide clues to the phenotypes that might be observed in humans having genetic disorders of adrenergic receptor function.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048638-05
Application #
5213982
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Tomita, Naruya; Kim, John Y S; Gibbons, Gary H et al. (2004) Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int J Mol Med 13:629-36
Daviet, L; Lehtonen, J Y; Hayashida, W et al. (2001) Intracellular third loops in AT1 and AT2 receptors determine subtype specificity. Life Sci 69:509-16
Pollman, M J; Naumovski, L; Gibbons, G H (1999) Endothelial cell apoptosis in capillary network remodeling. J Cell Physiol 178:359-70
Pollman, M J; Naumovski, L; Gibbons, G H (1999) Vascular cell apoptosis: cell type-specific modulation by transforming growth factor-beta1 in endothelial cells versus smooth muscle cells. Circulation 99:2019-26
Lou, X J; Kwan, H H; Prionas, S D et al. (1998) Despite its homology to angiostatin apolipoprotein(a) does not affect angiogenesis. Exp Mol Pathol 65:53-63
Laudanna, C; Campbell, J J; Butcher, E C (1997) Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem 272:24141-4
McEvoy, L M; Jutila, M A; Tsao, P S et al. (1997) Anti-CD43 inhibits monocyte-endothelial adhesion in inflammation and atherogenesis. Blood 90:3587-94
Cooke, J P; Creager, S J; Scales, K M et al. (1997) Role of digital artery adrenoceptors in Raynaud's disease. Vasc Med 2:1-7
Boonmark, N W; Lou, X J; Yang, Z J et al. (1997) Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100:558-64
Theilmeier, G; Chan, J R; Zalpour, C et al. (1997) Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vasc Biol 17:3557-64

Showing the most recent 10 out of 38 publications